Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity
Related Experiment Video
Updated: May 2, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
C Lanvers-Kaminsky1, I Malath1, D Deuster2
1Department of Pediatric Hematology and Oncology, University Children's Hospital of Muenster, Muenster, Germany.
No abstract available in PubMed .
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets

